Amgen Inc.

Innunex Corporation

Kenneth Allan Brasel

Douglas Pat Cerretti

Christopher Mehlin

James F Smothers

Kara Olson

Dauphine S Barone

Jose Carlos Escobar

Jacqueline A Kirchner

Eugene Maraskovsky

Charles R Maliszewski

David Haskett Lynch

Hilary Jean McKenna

Luis G Borges

Jilin Sun

Stephen Foster

Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of c-fms to CSF-1, reduce monocyte migration into tumors, and reduce the accumulation of tumor-associated macrophages.

Human C-FMS antigen binding proteins

Human C-FMS antibodies

Methods for treating conditions associated with c-fms

Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.

Nucleic acid molecule encoding human GM-CSF antigen binding proteins

Human GM-CSF antigen binding proteins

Flt3-ligand can be used to generate large numbers of dendritic cells from hematopoietic progenitor and stem cells. Flt3-ligand can be used to augment immune responses in vivo, and expand dendritic cells ex vivo. Such dendritic cells can then be used to present tumor, viral or other antigens to naive T cells, can be useful as vaccine adjuvants. When flt3-L is used and/or administered in combination with other reactive agents, e.g. CD40 binding proteins and 4-1BBL or antibodies reactive with 4-1BB, the combination further enhances immune responses and the effectiveness of vaccine adjuvants.

Methods of preparing dendritic cells with flt3-ligand and antigen

Growing community of inventors

Seattle, WA, United States of America

Kenneth Allan Brasel